26/2/2025, 10:45:04 am

Cipla says bring on US Tariffs, Indian generics to maintain edge

Cipla's CEO, Umang Vohra, expressed confidence that US tariffs and regulations won't impact Indian generics' competitiveness, viewing them as long-term positives. He highlighted Cipla's readiness to capitalize on GLP-1 and semaglutide opportunities in India. Nomura maintained a "Buy" rating on Cipla with a March 2026 target price of Rs 1,780, indicating a 22% upside based on earnings expectations.